Reversal of the Nephrotic Syndrome by Colchicine in Amyloidosis of Familial Mediterranean Fever
Authors: Deborah Zemer, Avi Livneh, Pnina Langevitz
Journal: Annals of Internal Medicine (1992)

Letters1 March 1992Reversal of the Nephrotic Syndrome by Colchicine in Amyloidosis of Familial Mediterranean FeverDeborah Zemer, MD, Avi Livneh, MD, Pnina Langevitz, MDDeborah Zemer, MD, Avi Livneh, MD, Pnina Langevitz, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-5-426_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Preventive long-term treatment with colchicine (using an appropriate daily dosage) may reduce kidney damage to minimal proteinuria in patients with familial mediterranean fever, even when it is introduced in the nephrotic stage of this amyloidotic renal disease. We are writing to correct our previous statement that colchicine does not affect amyloidotic kidney disease once it has reached the nephrotic stage (1). We report three cases in which colchicine treatment reduced such kidney damage.We treated a 40-year-old man of Jewish Sephardi origin who has had febrile attacks since the age of 6 months. In 1981, colchicine treatment,...References1. ZemerPrasSoharModanCabiliGafni DMEMSJ. Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever. N Engl J Med. 1986;314:1001-5. CrossrefMedlineGoogle Scholar2. LivnehZemerSiegalLaorSoharPras ADBAEM. Colchicine prevents kidney-transplant amyloidosis in familial mediterranean fever. Nephron. [In press]. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The Heller Institute of Medical Research Tel Aviv Israel PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByColchicin: altes Medikament mit neuem NutzenIL-1 blockers together with colchicine may be administered as first line therapy in familial Mediterranean fever with amyloidosisFamilial Mediterranean FeverApproach to the patients with inadequate response to colchicine in familial Mediterranean feverAnakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosisAnakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosisAssessment of renal involvement in patients with familial Mediterranean fever: a clinical study from Ardabil, IranAutoinflammatory Diseases in DermatologyA Review: Treatment of Alzheimers Disease Discovered in Repurposed AgentsThe Impact of Familial Mediterranean Fever on Women's HealthA case of familial Mediterranean fever-associated systemic amyloidosisFamilial Mediterranean FeverAmyloidosis and Giant Cell Arteritis/Polymyalgia RheumaticaAA type renal amyloidosis secondary to FMF: a long-term follow-up in two patientsAnakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicineAnakinra chez un enfant souffrant de fièvre méditerranéenne familiale résistante à la colchicineColchicine – an Overview for Plant BiotechnologistsFamilial Mediterranean Fever and Cryptogenic CirrhosisTransmission of familial Mediterranean fever mutations following bone marrow transplantationCountry as the primary risk factor for renal amyloidosis in familial mediterranean feverMechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysisLong-term followup needed to define role of infliximab in treatment of renal amyloidosis: Comment on the case report by Elkayam et alEfficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean feverFamilial Mediterranean fever and its implications for fertility and pregnancyUrinary glycosaminoglycans in the course of familial Mediterranean feverSerum C-reactive protein levels during attack-free periods of familial Mediterranean feverColchicine: Where to Use, Where Not to Use?Late Occurrence of Chronic Renal Failure in Familial Mediterranean Fever after 20 Years of Colchicine TreatmentCécile Vigneau, MD, David Petrover, MD, and Jean-Daniel Sraer, MD, PhDPilot Tolerability Studies of Hydroxychloroquine and Colchicine in Alzheimer DiseaseAnti-inflammatory and Antioxidant Therapies in Alzheimer's DiseaseColchicine in the treatment of renal amyloidosis secondary to familial Mediterranean feverRegression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatmentThe Pharmacology and Therapeutic Aspects of ColchicineColchicine: 1998 updateFamilial Mediterranean feverPeritoneal Mesothelioma in Recurrent Familial PeritonitisInflammatory Processes — Anti-Inflammatory TherapyRational pharmacotherapy for Alzheimer's diseaseThe changing face of Familial Mediterranean FeverPharmacology of immunosuppressive medications used in renal diseases and transplantationInflammation and Alzheimer diseaseRegression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprineBiologic and clinical advances in familial Mediterranean feverCOLCHICINE TREATMENT OF AA AMYLOIDOSIS OF FAMILIAL MEDITERRANEAN FEVERAmyloidosis: Prognosis and treatmentColchicine in the treatment of AA and AL amyloidosisFamilial Mediterranean fever in the colchicine era: The fate of one familyFamilial Mediterranean Fever-Associated AmyloidosisColchicine and Secondary AmyloidosisAli Serdar Fak, MD, Cetin Ozener, MD, Emel Akoglu, MD 1 March 1992Volume 116, Issue 5Page: 426-426KeywordsAmyloidosisColchicineFeversKidneysProteinuriaRenal diseases Issue Published: 1 March 1992 PDF DownloadLoading ...